Projects and Grants per year
Personal profile
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
Post Doctoral Fellow, Baylor University
1987
Post Doctoral Fellow, Duke University
1986
Residency, University Of Kentucky
1983
Doctor of Medicine, University Of Kentucky
1980
Bachelor of Arts, University Of California - San Diego
1973
Fingerprint
Dive into the research topics where Dennis Karounos is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration from the last 5 years on country level. Dive into details by clicking on the dots.
Projects & Grants
- 21 Finished
-
Vascular Metabolic Memory in Type II Diabetes
Sherrow, J., Karounos, D. & Ratliff, S.
Carl T Hayden Medical Research Foundation
7/1/10 → 3/31/16
Project: Research project
-
TrialNet: Natural History of the Development of Type 1 Diabetes
Karounos, D. & Reynolds, L.
6/1/09 → 6/30/20
Project: Research project
-
Antisense oligonucleotide targeting hepatic Serum Amyloid A limits the progression of angiotensin II-induced abdominal aortic aneurysm formation
Shridas, P., Ji, A., Trumbauer, A. C., Noffsinger, V. P., Meredith, L. W., de Beer, F. C., Mullick, A. E., Webb, N. R., Karounos, D. G. & Tannock, L. R., Apr 2024, In: Atherosclerosis. 391, 117492.Research output: Contribution to journal › Article › peer-review
Open Access -
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
Jan 2024, In: The Lancet Diabetes and Endocrinology. 12, 1, p. 39-50 12 p.Research output: Contribution to journal › Article › peer-review
Open Access19 Scopus citations -
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
Jan 2024, In: The Lancet Diabetes and Endocrinology. 12, 1, p. 51-60 10 p.Research output: Contribution to journal › Article › peer-review
Open Access16 Scopus citations -
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Jul 13 2019, In: The Lancet. 394, 10193, p. 121-130 10 p.Research output: Contribution to journal › Article › peer-review
1820 Scopus citations -
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
Jul 13 2019, In: The Lancet. 394, 10193, p. 131-138 8 p.Research output: Contribution to journal › Article › peer-review
422 Scopus citations